Vivelle-Dot Available In The U.S. For Menopause Symptoms
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Vivelle-Dot Available In The U.S. For Menopause Symptoms

MIAMI, FL -- May 10, 1999 -- Novogyne Pharmaceuticals’ Vivelle-Dot(TM) (estradiol transdermal system), the world's smallest transdermal estrogen delivery system, has been launched in the United States for use in the treatment of the symptoms of menopause.

Like the original Vivelle(R) (estradiol transdermal system), Vivelle-Dot is available in four dosage strengths (.0375, .05, .075 and .10 mg/day), and provides prescribing physicians with broad dosing flexibility. In the most commonly prescribed dosage strength (.05 mg/day), Vivelle-Dot is about the size and thickness of a postage stamp.

By area, it is about one-third the size of Berlex’s Climara(R) and about one-quarter the size of Novartis’ Estraderm(R), the current U.S. market leaders.

The new patch utilises Noven's proprietary Dot Matrix(TM) adhesive technology and delivers 17(beta)-estradiol through the skin and into the bloodstream. 17(beta)-estradiol is identical to a woman's own estrogen, unlike those estrogen therapies derived from equine sources.

In the U.S., more than 40 million women are in the menopausal age range (between 45 and 59), and every 16 seconds another woman enters her 50s.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities